LungLife AI Director/PDMR Notification

July 8, 2021

8 July 2021

LungLife AI, Inc.
("LungLife" or the "Company") 

Director/PDMR Notification

LungLife  (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that it has been notified of the following transaction in the Company's common shares of US $0.0001 each (“Common Shares”) undertaken by directors.

The transactions were made in connection with the placing of new Common Shares in the capital of the Company as part of the Company’s admission to trading on AIM.

Roy Davis, Non-Executive Chair, has today purchased 14,204 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Davis now holds 14,204 Common Shares, representing approximately 0.06% of the outstanding share capital of the Company.

In addition, Andrew Boteler, Non-Executive Director, has today purchased 5,681 Common Shares at the placing price of 176.0 pence per share. Following this purchase, Mr Boteler now holds 5,681 Common Shares, representing approximately 0.02% of the outstanding share capital of the Company.

The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation.

Click Here to Read the Full Announcement

Subscribe for Email Alerts

This field is for validation purposes and should be left unchanged.
© 2020 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
magnifiercrossmenuchevron-down